I completed SBRT treatment for Gleason 7 (3+4) PCa at MSKCC in NYC in November 2021. My PSA was 8.7 right before the treatment. My doctor: Dr. Michael Zelefsky.
Since that time:
-- My PSA as of May 2024 is 1.32.
-- I've had no real urinary issues since treatment except for some bouts of urgency especially after sitting for a while or after long car rides.
-- I've had no bowel or rectal issues.
-- Sexual function is normal and consistent (I'm still taking Sildenafil but I don't know if that has actually been a help or just a placebo because I've been on it since the treatment). Surprisingly enough, I still have some ejaculation all this time after treatment.
After being a patient at MSKCC for close to 15 years, I was notified early this year that they might not continue to accept my current insurance as "in-network." There have been quite a few contract negotiations and extensions, but it did make me uneasy as I didn't want to be caught unable to afford appointments and follow-ups. That prompted me to contact Dr. Michael Zelefsky (who has subsequently departed MSKCC) and make an appointment with him at NYU/Langone.
After reviewing my current PSA and the time since my SBRT treatment, Dr. Zelefsky recommended I undergo an MRI -- Not because there is anything outwardly suspicious, but mainly because I'm still under 60 years of age.
I just had the MRI last week, and the report revealed:
-- "No findings suspicious for prostate cancer."
-- "Peripheral zone: Decreased T2 signal likely Inflammatory."
-- "Transition zone: Enlarged and heterogeneous in appearance - consistent with BPH."
-- "No evidence of EPE."
-- "No evidence of seminal vesicle invasion. "
-- "No pathologic pelvic lymph nodes."
-- "No aggressive osseous lesion."
In addition, it appears my prostate has shrunk a bit.
Overall, I am extremely grateful for this outcome!
It's unfortunate that I must leave MSKCC -- all my experiences have been fantastic and the staff is wonderful -- but I am very happy to be under Dr. Michal Zelefsky's care again and to not think about insurance issues for the foreseeable future.